ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a putative class action

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42 nd Annual J.P.

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of the study’s dose-escalation portion is complete, with final

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will participate

New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad range of tumor targets RDT platform offers unique approach for tailored delivery of radioactive

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present in a